<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273373</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-AKI-03</org_study_id>
    <nct_id>NCT04273373</nct_id>
  </id_info>
  <brief_title>Low Dose Albumin Versus Standard Dose Albumin in Spontaneous Bacterial Peritonitis With Acute Kidney Injury.</brief_title>
  <official_title>A Randomized Non-inferiority Trial Comparing Low Dose Albumin Versus Standard Dose Albumin in Spontaneous Bacterial Peritonitis With Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM:- A randomized non-inferiority trial comparing low dose albumin versus standard dose
      albumin in Spontaneous Bacterial Peritonitis with acute kidney injury

      Methodology In this non-inferior randomized controlled trial one group will receive Low dose
      albumin: 20% albumin.5 g/kg at diagnosis and 0.5 g/kg till 5 days and other group will
      receive Standard dose albumin: 20% albumin1.5 g/kg at diagnosis and 1 g/kg at 48 h (duration
      of infusion 24 hours).

      Study population: Patients of age &gt; 18 years of age with cirrhosis of liver who are admitted
      in ward/Intensive Care Unit diagnosed with Spontaneous Bacterial Peritonitis.

      Study design: Randomized controlled trial Study period: September 2019- September 2020 Sample
      size: 300 (150 cases in each group) If there is a true difference in favour of the
      experimental treatment of 5 % then 270 patients are required to be 80% sure that the upper
      limit of a one sided 95% confidence interval (or equivalently a 90 % two-sided confidence
      interval) will exclude a difference in favour of the standard group of more than 5 %. And if
      the investigators consider 10% drop out final sample size is 270+30=300. 150 in each limb.
      Cases will be randomly allocated in 2 groups by block randomization method with block size
      taken as 10.

      Monitoring and assessment: all the parameters of the objective and also noted any adverse
      effects.

      Adverse Effects: Nausea, Vomiting, Fever with chills, dyspnea Stopping Rule: in the event of
      any of the adverse effects during therapy.

      Expected Outcome of the project:

      Proportion of patients having progression of Acute Kidney Injury by day 7
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 20, 2020</start_date>
  <completion_date type="Anticipated">February 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients having progression of Acute Kidney Injury in both groups</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with resolution of Spontaneous Bacterial Peritonitis in both groups</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PRA (Plasma Renin Activity) in both groups</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in TNF-alpha (Tumor Necrosis Factor) in both groups</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IL-6 (Interleukin) in both groups</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will develop volume overload in both groups</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will not survive in both groups.</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will not survive in both groups.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Standard dose albumin+SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20% albumin1.5 g/kg at diagnosis and 1 g. SOC (Standard of Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose albumin+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% albumin.5 g/kg at diagnosis and 0.5 g/kg. SOC (Standard of Care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low Dose Albumin</intervention_name>
    <description>20% albumin.5 g/kg at diagnosis and 0.5 g/kg till 5days</description>
    <arm_group_label>Low dose albumin+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard dose Albumin</intervention_name>
    <description>20% albumin1.5 g/kg at diagnosis and 1 g/kg at 48 h (duration of infusion 24 hours).</description>
    <arm_group_label>Standard dose albumin+SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18 years of age

          2. Cirrhosis with SBP (community acquired, health care associated and nosocomial) and
             baseline serum bilirubin ≥4 mg/dl or SCr ≥ 1 mg/dl.

        Exclusion Criteria:

          1. Antibiotic treatment within one week before the diagnosis of SBP (except for
             prophylactic treatment with norfloxacin)

          2. Significant cardiac failure, pulmonary disease

          3. Known CKD ( Chronic Kidney Disease)or findings suggestive of organic nephropathy
             (proteinuria, haematuria, or Abnormal findings on renal USG)

          4. Hepatocellular carcinoma

          5. HIV (Human Immunodeficiency Virus) infection;

          6. GI (Gastrointestinal) bleed within 1 month before the study

          7. Ileus

          8. Grade 3 to 4 hepatic encephalopathy

          9. Other types of infection

         10. Shock

         11. Presence of any potential causes of dehydration (such as diarrhoea or an intense
             response to diuretic treatment) within one week before the diagnosis of SBP).

         12. Baseline serum bilirubin &lt;4 mg/dl or S. Cr &lt; 1 mg/dl

         13. Serum creatinine level of &gt; 3.0 mg/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Pinakee Sunder Kar, MD</last_name>
    <phone>01146300000</phone>
    <email>pinakeesunder@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Pinakee Sunder Kar, MD</last_name>
      <phone>01146300000</phone>
      <email>pinakeesunder@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

